Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 6:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1561–1584 of 4,172 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Prostate Clear all
Terminated Phase 1Phase 2 Interventional Results available

HDR Brachytherapy, EBRT and STAD for the Treatment of Prostate Cancer

NCT03553602
View directory record Official record
Conditions
Prostate Cancer - Recurrent
Interventions
HDR Brachytherapy + EBRT + STAD
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years to 99 Years · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 30, 2026, 6:45 AM EDT
Completed No phase listed Observational

Stockholm3 Validation Study in a Multi-Ethnic Cohort

NCT04583072
View directory record Official record
Conditions
Prostate Cancer (Diagnosis)
Interventions
The Stockholm3 test
Diagnostic Test
Lead sponsor
Karolinska Institutet
Other
Eligibility
45 Years to 75 Years · Male only
Enrollment
2,152 participants
Timeline
2019 – 2023
U.S. locations
13
States / cities
Los Angeles, California • Palo Alto, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Oct 30, 2026, 6:45 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)

NCT03493945
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer, Prostate Cancer, Prostate Neoplasm, Advanced Solid Tumor, Solid Tumor, Non-metastatic Castration-resistant Prostate Cancer
Interventions
M7824, N-803, MVA-BN-Brachyury, FPV-Brachyury, Epacadostat, Acetaminophen, Ibuprofen, Naproxen, Benadryl, EKG, Bone scan, CT chest, abdomen and pelvis, MRI
Biological · Drug · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Oct 30, 2026, 6:45 AM EDT
Completed Phase 2 Interventional

Study Using CP-461 to Treat Advanced Prostate Cancer

NCT00036075
View directory record Official record
Conditions
Prostate Cancer
Interventions
CP-461
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
2
States / cities
New York, New York • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 17, 2011 · Synced Oct 30, 2026, 6:45 AM EDT
Completed Phase 1 Interventional

Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors

NCT00413322
View directory record Official record
Conditions
Tumor
Interventions
belinostat, 5-Fluorouracil (5-FU)
Drug
Lead sponsor
Valerio Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
3
States / cities
Scottsdale, Arizona • Omaha, Nebraska • Portsmouth, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 8, 2015 · Synced Oct 30, 2026, 6:45 AM EDT
Terminated Phase 3 Interventional Results available

Randomized Trial of Adjuvant Hormonal Therapy in Surgically Treated Prostate Cancer Patients at High Risk for Recurrence

NCT00003645
View directory record Official record
Conditions
Prostate Cancer
Interventions
Flutamide, Leuprolide Acetate
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 28, 2020 · Synced Oct 30, 2026, 6:45 AM EDT
Completed Not applicable Interventional

Staying Strong and Healthy During Androgen Deprivation Therapy (ADT) for Men

NCT02969577
View directory record Official record
Conditions
Prostate Cancer
Interventions
Exercise Program, Diet and Nutrition Coaching, Usual Care with Attention
Behavioral · Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
21 Years and older · Male only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Los Angeles, California • Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Oct 30, 2026, 6:45 AM EDT
Terminated Phase 1Phase 2 Interventional

A Phase I/II Open-label Study of MCS110 in Patients With Prostate Cancer and Bone Metastases

NCT00757757
View directory record Official record
Conditions
Prostate Cancer, Bone Metastases
Interventions
MCS110
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Las Vegas, Nevada • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 30, 2026, 6:45 AM EDT
Active, not recruiting Not applicable Interventional

UFPTI 2403-PR12: Real-Time Volumetric Ionizing Radiation Acoustic Imaging for In-vivo Proton Treatment Monitoring in Pencil-Beam Scanning

NCT06465966
View directory record Official record
Conditions
Prostate Cancer
Interventions
iRAI
Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 30, 2026, 6:45 AM EDT
Active, not recruiting Not applicable Interventional

Germline DNA-Based Radiosensitivity Biomarker Influence on Toxicity Following Prostate Radiotherapy, GARUDA Trial

NCT04624256
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8
Interventions
Discussion, Hypofractionated Radiation Therapy, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
Procedure · Radiation · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 30, 2026, 6:45 AM EDT
Completed Phase 1 Interventional

Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors

NCT00058253
View directory record Official record
Conditions
Recurrent Prostate Cancer, Stage IV Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
tanespimycin, docetaxel
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 17, 2014 · Synced Oct 30, 2026, 6:45 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1

NCT03837353
View directory record Official record
Conditions
Prostate Cancer
Interventions
DKN-01, Docetaxel
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
5
States / cities
San Francisco, California • Baltimore, Maryland • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Oct 30, 2026, 6:45 AM EDT
Completed No phase listed Observational Results available

Prostate Cancer Screening in Men With Germline BRCA2 Mutations

NCT02154672
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
30 Years to 90 Years · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 9, 2021 · Synced Oct 30, 2026, 6:45 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study of Erlotinib in Patients With Non-Metastatic Prostate Cancer With a Rising Prostate Specific Antigen (PSA) on Hormone Therapy

NCT00148772
View directory record Official record
Conditions
Prostate Cancer
Interventions
Erlotinib (Tarceva)
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years and older · Male only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
2
States / cities
Chicago, Illinois • Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 28, 2011 · Synced Oct 30, 2026, 6:45 AM EDT
Completed Early Phase 1 Interventional

Cisplatin in Castration Resistant Prostate Cancer

NCT03275857
View directory record Official record
Conditions
Prostate Cancer
Interventions
Cisplatin
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 10, 2024 · Synced Oct 30, 2026, 6:45 AM EDT
Completed Phase 2 Interventional Results available

ET 743 (Yondelis) in Men With Advanced Prostate Cancer

NCT00147212
View directory record Official record
Conditions
Prostate Cancer
Interventions
ET 743
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 30, 2026, 6:45 AM EDT
Completed No phase listed Observational

A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Tetraxetan Treated Patients

NCT07477756
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 30, 2026, 6:45 AM EDT
Completed No phase listed Observational

GentleCath™ for Men Intermittent Catheter With FeelClean™ Technology

NCT05470751
View directory record Official record
Conditions
Bladder Outlet Obstruction, Multiple Sclerosis, Cauda Equina Syndrome, Enlarged Prostate With Lower Urinary Tract Symptoms, Parkinson Disease, Lower Urinary Tract Symptoms, Detrusor Underactivity, Spinal Cord Injuries
Interventions
Intermittent self-catheterisation
Device
Lead sponsor
ConvaTec Inc.
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
West Orange, New Jersey • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Oct 30, 2026, 6:45 AM EDT
Completed Phase 2 Interventional Results available

Tecemotide (L-BLP25) in Prostate Cancer

NCT01496131
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radiation therapy, Goserelin, Cyclophosphamide, Tecemotide (L-BLP25)
Radiation · Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older · Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 9, 2018 · Synced Oct 30, 2026, 6:45 AM EDT
Active, not recruiting Not applicable Interventional

Expander-2 Trial: Randomized Study to Evaluate Safety & Efficacy of the Urocross® Expander System & Retrieval Sheath

NCT05400980
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Urocross implant, Sham-control
Device · Diagnostic Test
Lead sponsor
Prodeon Medical, Inc
Industry
Eligibility
45 Years and older · Male only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
2
States / cities
Maywood, Illinois • Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 30, 2026, 6:45 AM EDT
Completed Phase 2 Interventional Results available

S0354, Anti-IL-6 Chimeric Monoclonal Antibody in Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

NCT00433446
View directory record Official record
Conditions
Prostate Cancer
Interventions
CNTO 328
Biological
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older · Male only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
123
States / cities
Anniston, Alabama • Springdale, Arkansas • Berkeley, California + 77 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2013 · Synced Oct 30, 2026, 6:45 AM EDT
Not listed Phase 1 Interventional

Chemotherapy for Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

NCT00090727
View directory record Official record
Conditions
Solid Malignancies, Non-Hodgkin's Lymphoma
Interventions
AQ4N
Drug
Lead sponsor
Novacea
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
2
States / cities
The Bronx, New York • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2006 · Synced Oct 30, 2026, 6:45 AM EDT
Completed Phase 1 Interventional

An Investigational Scan (rh PSMA 7.3 PET/MRI) for the Detection of Recurrent Disease and Aid in Radiotherapy Planning in Biochemically Recurrent Prostate Cancer

NCT04978675
View directory record Official record
Conditions
Biochemically Recurrent Prostate Carcinoma, Localized Prostate Carcinoma, Prostate Adenocarcinoma
Interventions
Fluorine F 18 rhPSMA-7.3, Magnetic Resonance Imaging, Positron Emission Tomography
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Oct 30, 2026, 6:45 AM EDT
Not yet recruiting Phase 3 Interventional

Multiparametric Ultrasound for the Diagnosis of Clinically Significant Prostate Cancer

NCT06024772
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
ultiparametric Magnetic Resonance Imaging, Perflutren lipid microsphere, Transrectal Ultrasound, Biopsy of Prostate
Procedure · Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older · Male only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 30, 2026, 6:45 AM EDT